# A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

> **NCT03652051** · PHASE2 · COMPLETED · sponsor: **Azura Ophthalmics** · enrollment: 321 (actual)

## Conditions studied

- Meibomian Gland Dysfunction
- Dry Eye

## Interventions

- **DRUG:** AZR-MD-001 Low Dose
- **DRUG:** AZR-MD-001 Mid Dose
- **DRUG:** AZR-MD-001 High Dose
- **DRUG:** AZR-MD-001 Vehicle

## Key facts

- **NCT ID:** NCT03652051
- **Lead sponsor:** Azura Ophthalmics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-10
- **Primary completion:** 2022-09-14
- **Final completion:** 2022-10-19
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652051, "A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03652051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*